Quarterly ResultMay 11, 2026, 04:18 PM
CVRx Q1 Revenue $14.8M (+20%); Net Loss $13.1M; Updates Guidance
AI Summary
CVRx, Inc. reported strong financial and operating results for the first quarter of 2026, with total revenue increasing 20% to $14.8 million and U.S. revenue growing 22% to $13.7 million. The company's net loss improved to $13.1 million, or $0.50 per share. Operational highlights include growth in active U.S. implanting centers and the activation of the first site and enrollment of the first patient in the BENEFIT-HF clinical trial. CVRx maintained its full-year 2026 revenue guidance and updated its gross margin outlook.
Key Highlights
- Total revenue for Q1 2026 was $14.8 million, an increase of 20% over Q1 2025.
- U.S. revenue for Q1 2026 was $13.7 million, an increase of 22% over Q1 2025.
- Net loss for Q1 2026 was $13.1 million, or $0.50 per share, compared to $13.8 million ($0.53 per share) in Q1 2025.
- Gross profit for Q1 2026 was $12.9 million, up 25%, with gross margin at 87% (vs 84% in Q1 2025).
- Active U.S. implanting centers grew to 257 as of March 31, 2026, from 227 a year prior.
- First site activated and first patient enrolled in the BENEFIT-HF clinical trial.
- Full-year 2026 revenue guidance maintained at $63.0 million to $67.0 million.
- Q2 2026 revenue expected between $15.1 million and $16.1 million.